StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

TARSBullishAnalyst Target Updateanalyst
High materiality7/10

Tarsus Pharmaceuticals reinstated with an Overweight at Barclays

Sep 16, 2026, 7:29 AM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Analyst target changes matter most when the new target creates a material gap versus current price or confirms a recent catalyst.

AI summary

What happened, with direct paths to the underlying reporting

Barclays upgrades TARS to Overweight; target 110; price 78.23.

  • Barclays upgrades TARS to Overweight; target 110; price 78.23.

Key facts

  1. 01

    Target: $110

  2. 02

    Posted price: $78.23

  3. 03

    Analyst firm: Barclays

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.